BioNTech erweitert fortgeschrittenes klinisches Onkologie-Portfolio: Weiterer Phase-2-Studienstart mit mRNA-basierter individualisierter Neoantigen-spezifischer Immuntherapie in neuer Krebsindikation
19 oct. 2023 06h45 HE
|
BioNTech SE
Grundlage für Phase-2-Studienstart waren Daten einer klinischen Phase-1-Studie zur Untersuchung der Sicherheit und Verträglichkeit von Autogene Cevumeran (BNT122, RO7198457) in Kombination mit...
BioNTech Expands Late-Stage Clinical Oncology Portfolio with Initiation of further Phase 2 Trial with mRNA-based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication
19 oct. 2023 06h45 HE
|
BioNTech SE
Initiation of Phase 2 builds on data from a Phase 1 clinical trial evaluating the safety and tolerability of autogene cevumeran (BNT122, RO7198457) in combination with the anti-PD-L1 immune checkpoint...
Vaccinex to Present Update on PDAC/Pepinemab Study; New ActivMAb® Application
27 sept. 2023 08h00 HE
|
Vaccinex, Inc.
Phase 1b/2 pepinemab/PDAC study update to be presented on September 29 at special AACR meeting New ActivMAb® application to be reviewed on September 28 at CHI's 20th Annual Discovery on...
Government’s Critical Minerals Strategy Recognizes Canada’s Once-in-a-Generation Opportunity to Lead Low Carbon Transition
09 déc. 2022 13h30 HE
|
Prospectors & Developers Association of Canada (PDAC)
VANCOUVER, British Columbia, Dec. 09, 2022 (GLOBE NEWSWIRE) -- The Prospectors & Developers Association of Canada (PDAC) is encouraged to see its recommendations on behalf of Canada’s mineral...
Oncotelic Reports Q3 2022 Compared to Q3 2021 Financial Results
21 nov. 2022 09h00 HE
|
Oncotelic Therapeutics, Inc.
R&D cost reduced in excess of 95% while continuing expansion of our OT-101 clinical programs through our joint ventureG&A cost reduced by approximately 50%Net loss reduced by approximately...
Oncotelic Publishes SITC Meeting 2022 Presentation Materials
16 nov. 2022 08h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We"), a developer of treatments for rare and orphan indications,...
LICY FINAL DEADLINE NOTICE: ROSEN, A LONGSTANDING LAW FIRM, Encourages Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. Investors to Secure Counsel Before Important June 21 Deadline in Securities Class Action Filed by the Firm – LICY, PDAC
19 juin 2022 13h00 HE
|
The Rosen Law Firm PA
NEW YORK, June 19, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp....
LICY FINAL DEADLINE ALERT: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp. Investors with Losses to Secure Counsel Before Important June 20 Deadline in Securities Class Action Filed by the Firm – LICY, PDAC
13 juin 2022 16h45 HE
|
The Rosen Law Firm PA
NEW YORK, June 13, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Li-Cycle Holdings Corp. f/k/a Peridot Acquisition Corp....
Atlas Drills Another Large Step-Out at Great Atlantic
10 juin 2022 10h16 HE
|
Atlas Salt Inc.
ST. JOHN’S, Newfoundland and Labrador, June 10, 2022 (GLOBE NEWSWIRE) -- Atlas Salt (the “Company” or “Atlas” - TSXV: SALT) is pleased to report that as the Company progresses toward completion of...
South Grass Valley Carlin-Type Gold Project – June 2022 Update
09 juin 2022 09h00 HE
|
Nevada Exploration Inc.
RENO, Nev., June 09, 2022 (GLOBE NEWSWIRE) -- Highlights: Drillhole SGVC014 stopped at 534 metres due to lost tooling, being redrilled as SGVC014A, and now at 640 metres.Features of...